Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review.
This systematic review examines the use of platelet-rich plasma (PRP), growth factors (PDGF, TGF-β1, IGF-1, FGF, VEGF, BMPs), and the stable gastric pentadecapeptide BPC 157 in the treatment of tendon, ligament, and muscle injuries, as well as osteotendinous, myotendinous, and muscle-to-bone junction injuries. The authors frame these interventions under the concept of "cytoprotection," emphasizing restoration of tissue integrity. The review concludes that while growth factors delivered locally via carriers show improvements in tendon, ligament, and muscle healing, some (PDGF, TGF-β1, IGF-1) appear to have limited benefit in muscle lesions, and all show limited or no efficacy at junctional healing sites. By contrast, the authors argue that BPC 157 — proposed as a cytoprotection mediator — demonstrated consistent efficacy across tendon, ligament, muscle, and junctional injuries in rat studies, via both systemic (intraperitoneal, intragastric, drinking water) and local (topical cream) administration, without requiring carriers or scaffolds. The authors suggest translational potential for clinical use and call for further clinical trials. Key limitations include that the supporting evidence for BPC 157 is derived almost exclusively from preclinical (rat) studies, with no human clinical trial data presented.
Why this grade: Although framed as a systematic review, the BPC 157 evidence base described consists entirely of rat studies with no human clinical trial data, making the overall grade animal-only for that compound's efficacy claims.
As a novel theoretical and practical advantage, preclinical to clinical evidence, this systematic review of PRP, growth factors, and stable gastric pentadecapeptide BPC 157 efficacy in complex musculoskeletal and junctional injuries emphasizes the cytoprotection concept, healing to restore tissue integrity. Notably, the concept holds tendon, ligament, and muscle healing, in particular. Then, it holds their healing together as interconnected lesions. Consequently, this review presents the possibilities for cytoprotective therapies suited for tendon/ligament/muscle and recovery of osteotendinous, myotendinous, and the muscle-to-bone junction. The estimated key was the success of injury recovery amid each agent's direct exogenous administration, alone or with a carrier, locally or systemically, without reliance on complex scaffolds, carriers, or tissue-engineering constructs. As reviewed, while with commonly acknowledged physiological significance, and acting throughout cytoprotection principles, growth factors (PDGF, TGF-β1, IGF-1, FGF, VEGF, BMPs) delivered locally with various carriers improve tendon, ligament, and muscle healing; however, some (PDGF, TGF-β1, IGF-1) may fail in muscle lesions, and all show limited or no efficacy in junctional healing. Contrarily, proposed as a cytoprotection mediator, BPC 157 acts alone with a full cytoprotection range, given systemically or locally. Moreover, without any carrier, BPC 157 acts alone, combining beneficial effects on tendon, ligament, and muscle injuries with osteotendinous, myotendinous, and muscle-to-bone healing. In rat studies, across systemic (intraperitoneal, intragastric, or drinking water) and local (cream) administration, BPC 157 consistently demonstrated efficacy, indicating considerable translational potential. Further clinical studies will strengthen cytoprotective therapy and, particularly, BPC 157 in complex musculoskeletal and junctional injuries.
Educational summary of published research — not medical advice. License: cc by. Full text is shown only where licensing permits.